Trial Profile
Clinical Study to Assess the Safety fo AVI-4658 in Subjects With Duchenne Muscular Dystrophy Due to a Frame-shift Mutation Amenable to Correction by Skipping Exon 51
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Oct 2022
Price :
$35
*
At a glance
- Drugs Eteplirsen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors Sarepta Therapeutics
- 15 May 2014 New trial record